| AJCC | American Joint Committee on Cancer |
| ASCO | American Society of Clinical Oncology |
| bTMB | Blood tumor mutational burden |
| CI | Confidence interval |
| CPS | Combined positive score. |
| CTLA4 | Cytotoxic T lymphocyte Antigen 4 |
| DFS | Disease free survival |
| EMA | European Medicines Agency |
| FDA | Food and Drug Administration |
| HNSCC | Head and neck squamous cell carcinoma |
| HPV | Human papilloma virus |
| HR | Hazard ratio |
| IC | Investigators choice |
| IHC | Immunohistochemical staining |
| IS | Immunoscore |
| ISH | In situ hybridization |
| Mb | Megabase |
| NCI | National Cancer Institute |
| NGS | Next generation sequencing |
| OPSCC | Oropharyngeal squamous cell carcinoma |
| OS | Overall survival |
| PCR | Polymerase chain reaction |
| PD-1 | Programmed Cell Death Protein 1 |
| PD-L1 | Programmed death ligand-1 |
| RSI | Radiosensitivity Index |
| SOC | Standard of car |
| TILs | Tumor infiltrating lymphocytes |
| TMB | Tumor mutational burden |
| TME | Tumor microenvironment |
| TNM | Tumor, node, metastasis |
| TPS | Tumor proportion score |
| Tregs | Regulatory T-cells |
| UICC | Union for International Cancer Control |
| US | United States |